knowledge -WSS

knowledge

author：entertainment 2025-09-03 22:34:57 - browse：79

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

leisure time

WSS

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Hospitals warn Medicare's drug payment fix is ‘unlawful’

FDA has safety concerns on CRISPR

Virtual repurposing can help discover new uses for existing drugs

CDC recommends rationing of RSV shot due to shortages

explore

knowledge

knowledge

Drug repurposing or repositioning? The language matters

Are embryos people? Reproductive medicine's future depends on the answer

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Beam, Prozac, "TechBio" and more

The cancer drug shortage isn’t new — and neither are the solutions

Biden's order seeks to regulate AI risk without stifling innovation

Wildfire smoke exposes gaps in outdoor worker protections

Neuroscience renaissance leads to new crop of psychiatric drugs

Medicare details structure of new drug price negotiation program

Traditional Chinese medicine benefits explored in new JAMA study

focus

Telehealth options flood the market as retailers push virtual care

Cassava reveals details — and problems — with Alzheimer's study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Pfizer is about to make a big push in cancer. Will investors listen?

Children’s Hospital revives plan for pedestrian bridge

entertainment

leisure time

focus

entertainment